MedTrace Logo

Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery

NCT02736578 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-06-25

Study results available
· View outcomes & findings →

Summary

This phase 1-2 trial studies the side effects and best dose of cetuximab-IRDye 800CW when used with intraoperative imaging, to determine the utility of cetuximab-IRDye 800CW to identify and assess pancreatic cancer in patients undergoing surgery to remove the tumor. Cetuximab-IRDye 800CW may help doctors better identify cancer in the operating room by making the cancer visible when viewed through a fluorescent imaging system.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DRUG

Cetuximab-IRDye800

Administered intravenously (IV) at 50 or 100 mg

DRUG

Cetuximab

Administered as a 100 mg IV loading dose

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eben Rosenthal

    lead OTHER

Principal Investigators

  • George Poultsides, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-04-24
Completion
2017-05-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02736578 on ClinicalTrials.gov